A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trial

ClinicoEconomics and Outcomes Research

Volumn 10, Issue , 2018, Pages 67-74

  Baker, Christine L ^a   Pietri, Guilhem ^b  

^a PFIZER INC   (United States)

^b Data Pyxis Ltd   (United Kingdom)

Author keywords

BENESCO model; Cost effectiveness; EAGLES trial; Smoking cessation; Smoking related morbidity; Smoking related mortality; Varenicline

Indexed keywords

AMFEBUTAMONE; VARENICLINE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LUNG CANCER; MALE; MORBIDITY; MORTALITY; NICOTINE REPLACEMENT THERAPY; SMOKING CESSATION; UNITED STATES;

EID: 85041547877     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S153897     Document Type: Article

References (30)

1. World Health Organization. Economics of Tobacco Toolkit: Assessment of the Economic Costs of Smoking; 2011. Available from: http:// apps.who.int/iris/bitstream/10665/44596/1/9789241501576_eng.pdf. Accessed August 29, 2017.
2. World Health Organization [webpage on the Internet]. Tobacco Fact sheet, No. 339; 2017. Available from: http://www.who.int/mediacentre/ factsheets/fs339/en/. Accessed August 29, 2017.
3. Jamal A, Agaku IT, O’Connor E, King BA, Kenemer JB, Neff L. Current cigarette smoking among adults - United States, 2005-2013. MMWR Morb Mortal Wkly Rep. 2014;63(47): 1108-1112.
4. U.S. Department of Health and Human Services. The Health Consequences of Smoking - 50 Years of Progress. A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
5. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008.
6. Babb S, Malarcher A, Schauer G, Asman K, Jamal A. Quitting smoking among adults - United States, 2000-2015. MMWR Morb Mortal Wkly Rep. 2017;65(52): 1457-1464.
7. National Institute for Health and Care Excellence [webpage on the Internet]. Smoking: Supporting People to Stop, Quality Standard [QS43]; Quality Statement 3; 2013. Available from: https://www.nice. org.uk/guidance/qs43. Accessed August 29, 2017.
8. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037): 2507-2520.
9. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;(5): CD009329.
10. Hughes JR, Solomon LJ, Naud S, Fingar JR, Helzer JE, Callas PW. Natural history of attempts to stop smoking. Nicotine Tob Res. 2014;16(9): 1190-1198.
11. Ruger JP, Lazar CM. Economic evaluation of pharmaco- and behavioral therapies for smoking cessation: a critical and systematic review of empirical research. Annu Rev Public Health 2012;33: 279-305.
12. Woolacott NF, Jones L, Forbes CA, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess. 2002;6(16): 1-245.
13. Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics. 2008;26(6): 497-511.
14. Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA. 2000;284(6): 706-712.
15. Steel Z, Marnane C, Iranpour C, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980-2013. Int J Epidemiol. 2014;43(2): 476-493.
16. Nides M, Glover ED, Reus VI, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav. 2008;32(6): 664-675.
17. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Natl Vital Stat Rep. 2013;61(4): 1-117.
18. US Census Bureau PD. Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States, States, Counties, and Puerto Rico Commonwealth and Municipios: April 1, 2010 to July 1, 2014; 2014. Available from: https://factfinder.census.gov/faces/ tableservices/jsf/pages/productview.xhtml?src~bkmk. Accessed August 29, 2017.
19. Schiller JS, Lucas JW, Peregoy JA. Summary health statistics for U.S. Adults: national health interview survey, 2011. Vital Health Stat 10. 2012;(256): 1-218.
20. Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for U.S. adults: national health interview survey, 2012. Vital Health Stat 10. 2014;(260): 1-161.
21. Kochanek KD, Murphy SL, Xu J. National Vital Statistics Reports. Deaths: Final Data for 2011; 2015. Available from: https://www. cdc.gov/nchs/data/nvsr/nvsr63/nvsr63_03.pdf. Accessed August 29, 2017.
22. National Cancer Institute [webpage on the Internet]. SEER Cancer Statistics Review 1975-2011; 2011. Available from: http://seer.cancer. gov/csr/1975_2011/browse_csr.php?sectionSEL~15&pageSEL~s ect_15_table.27.html. Accessed August 29, 2017.
23. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation. 2014;129(3): e28-e292.
24. Kissela BM, Khoury JC, Alwell K, et al. Age at stroke: temporal trends in stroke incidence in a large, biracial population. Neurology. 2012;79(17): 1781-1787.
25. Kleindorfer DO, Khoury J, Moomaw CJ, et al. Stroke incidence is decreasing in whites but not in blacks: a population-based estimate of temporal trends in stroke incidence from the Greater Cincinnati/ Northern Kentucky Stroke Study. Stroke. 2010;41(7): 1326-1331.
26. Blanchette CM, Gross NJ, Altman P. Rising costs of COPD and the potential for maintenance therapy to slow the trend. Am Health Drug Benefits. 2014;7(2): 98-106.
27. Folse HJ, Goswami D, Rengarajan B, Budoff M, Kahn R. Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study. Atherosclerosis. 2014;236(1): 154-161.
28. Lee WC, Christensen MC, Joshi AV, Pashos CL. Long-term cost of stroke subtypes among Medicare beneficiaries. Cerebrovasc Dis. 2007;23(1): 57-65.
29. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2): 117-128.
30. First Databank [webpage on the Internet]. FDB MedKnowledge™; 2014. Available from: http://www.fdbhealth.com/solutions/fdb-medknowledge/. Accessed June 1, 2014.